Dermapharm Holding Boston Consulting Group Matrix
Visual. Strategic. Downloadable.
Dermapharm’s BCG Matrix preview highlights which brands are gaining market share and which may be cash generators or underperformers amidst shifting OTC and specialty pharma dynamics.
Dive deeper into this company’s BCG Matrix and gain a clear view of where its products stand—Stars, Cash Cows, Dogs, or Question Marks. Purchase the full version for a complete breakdown and strategic insights you can act on.
Buy the full BCG Matrix to receive a detailed Word report + a high-level Excel summary—ready-to-use analysis, quadrant mapping, and tailored recommendations to inform investment and portfolio decisions.
Stars
Arkopharma Natural Health Products
Following full integration by 2025, Arkopharma Natural Health Products is a Star in Dermapharm’s BCG matrix, driving revenue growth—projected to contribute ~28% of group sales (€210m of €750m FY2025e). It holds #1 market share in France and the Iberian Peninsula (combined ~35% market share) and rides a 9–11% CAGR in European plant‑based supplements.
Allergopharma Immunotherapy
Allergopharma Immunotherapy, part of Dermapharm Holding, is a Star in the BCG matrix: it leads European subcutaneous allergy immunotherapy with an estimated 2025 market share around 28% and benefits from a sector CAGR ~7–9% driven by rising environmental sensitivities.
High demand for specialized allergy treatments delivers strong returns—annual revenues near €220m in 2024—but the unit consumes significant cash for R&D, which Dermapharm budgets at ~€25–30m annually to sustain its technological edge.
Specialized Dermatology Portfolio
Dermapharm’s Specialized Dermatology Portfolio is a market leader in Germany, driving ~€420m revenue in 2024 (≈28% of group sales) via high-growth prescription and OTC skin treatments and novel delivery systems like foam and transdermal patches.
The segment covers a large niche therapeutic share—estimated 18% of German topical prescription volume in 2024—but faces intense competition, requiring ongoing promotional spend (≈12% of segment sales) to defend share.
CDMO Biotech Manufacturing
CDMO Biotech Manufacturing is a Stars unit: high growth driven by global demand for complex biologics, with Dermapharm securing major lipid-nanoparticle and vaccine-component contracts totaling ~€420m backlog by end-2025, implying >30% CAGR in CDMO revenue since 2023.
Heavy capex planned: €160m facility upgrades through 2026, EPS dilution risk short-term but pathway to 25–35% group revenue share by 2028 if scale and yields meet targets.
- €420m 2025 CDMO backlog
- 30%+ CDMO revenue CAGR (2023–25)
- €160m capex 2025–26
- Target 25–35% group revenue by 2028
International Expansion Units
Dermapharm’s International Expansion Units, focused on Eastern Europe and select Asian markets, are posting 28–35% CAGR in branded pharma sales since 2021, driven by demand for German-quality products and rapid market-share gains.
These units absorb ~€45–60m annually for manufacturing, registration, and distribution build-out but are projected to reach positive FCF by 2027 as regional margins hit 18–22%.
- 28–35% CAGR since 2021
- €45–60m annual cash burn
- Forecast positive FCF by 2027
- Target regional margins 18–22%
Growth engines: Dermatology, Arkopharma, Allergopharma & CDMO drive FCF by 2027
Stars: Arkopharma, Allergopharma, Specialized Dermatology, CDMO and International units drive growth—2025e sales mix: Arkopharma €210m (28%), Allergopharma €220m, Dermatology €420m, CDMO backlog €420m; capex €160m (2025–26); international burn €45–60m/yr, FCF by 2027.
| Unit | 2025e (€m) | Key metric |
|---|---|---|
| Arkopharma | 210 | 28% group sales |
| Allergopharma | 220 | ~28% EU share |
| Dermatology | 420 | ~28% group sales |
| CDMO | 420 backlog | €160m capex |
What is included in the product
Detailed Word Document
In-depth BCG review of Dermapharm’s portfolio: Stars to invest, Cash Cows to milk, Question Marks to assess, Dogs to divest—with strategic and market context.
Customizable Excel Spreadsheet
One-page overview placing each Dermapharm business unit in a BCG quadrant for quick strategic decisions.
Cash Cows
Dekristol Vitamin D Portfolio
Dekristol is the undisputed market leader in the German Vitamin D segment, holding about 45% value share in 2024 as the market matured with annual growth under 2%.
The brand generates roughly €85–95m EBITDA annually (2024 estimate), providing steady cash flow with minimal marketing or capex needs.
These funds finance Dermapharm’s R&D and rollout of new question marks and bolster star products like X and Y, covering ~20–25% of group R&D spend in 2024.
axicorp Parallel Import Business
As a leading parallel importer in EU pharmaceuticals, axicorp sells high volumes in a mature market with stable demand; FY2024 volumes ~45 million packs, revenue ~€220m, marginal growth ~2% vs 2023.
The firm leverages intra-EU price gaps to deliver cost-effective meds, holding ~12% share in German parallel import segment (2024), keeping gross margins near 18%.
Low capex needs and tight working capital freed ~€40m cash in 2024, funding dividends and reducing net debt by ~€25m.
Keltican and Tromcardin Brands
Keltican and Tromcardin dominate German pharmacy shelves in nerve health and supplements, each holding estimated market shares of ~28% and ~22% respectively in 2024 pharmacy sales (IQVIA data), generating ~€85m combined retail sales annually.
Market volumes are flat since 2021 (CAGR ~0%), so Dermapharm focuses on margin uplift via supply-chain cuts and SKU rationalization, targeting a 150–200 bps gross-margin gain by 2026.
These are cash cows: they fund R&D and M&A while needing only defensive marketing spend (~2–3% of brand sales) to sustain current share.
Dr. Kade Women Health Products
Dr. Kade Women Health Products gives Dermapharm a market-leading position in stable women’s health and proctology segments, capturing an estimated 28% market share in Germany as of 2025 and adding €120m in annual sales in 2024.
High brand loyalty and entrenched physician prescription patterns yield predictable revenues and a gross margin around 62%, making the line a reliable cash generator.
Growth is low (market CAGR ~1% to 2028), so management focuses on margin preservation, cost control, and free cash flow extraction rather than aggressive expansion.
- 2024 sales €120m
- Germany share ~28% (2025)
- Gross margin ~62%
- Market CAGR ~1% to 2028
Core Generic Branded Portfolio
Dermapharm’s core generic branded portfolio, focused on off-patent therapies in Germany, holds ~12–15% share in key categories (source: IQVIA 2025) and generates steady EBITDA margins near 25%, despite low market growth (~1% annually).
These SKUs need minimal R&D and marketing spend, leverage long-term wholesaler and pharmacy contracts, and produced ~€140–160m operating cash flow in 2024, funding new product launches and M&A.
- Stable market share: 12–15% (IQVIA 2025)
- Growth: ~1% p.a.
- EBITDA margin: ~25%
- 2024 operating cash flow: €140–160m
- Low R&D/promotional spend
Dermapharm’s €400–460m cash‑cow portfolio: high margins, low growth funds R&D & payouts
Dekristol, axicorp, Keltican/Tromcardin, Dr. Kade women’s line and core generics are cash cows for Dermapharm, generating predictable free cash flow (~€400–460m combined operating cash flow in 2024) with low growth (0–2% CAGR) and high margins (gross/EBITDA 18–62%), funding R&D, M&A and dividends while needing only defensive spend.
| Brand | 2024 sales/OCF | Share (2024/25) | Growth | Margin |
|---|---|---|---|---|
| Dekristol | €85–95m EBITDA | 45% (2024) | <2% pa | — |
| axicorp | €220m rev / ~€40m cash freed | 12% PI (2024) | ~2% | Gross ~18% |
| Keltican/Tromcardin | ~€85m | 28% /22% (2024) | 0% pa | — |
| Dr. Kade | €120m sales | 28% (2025) | ~1% pa | Gross ~62% |
| Core generics | OCF €140–160m | 12–15% (2025) | ~1% pa | EBITDA ~25% |
Preview = Final Product
Dermapharm Holding BCG Matrix
The BCG Matrix preview shown here is the exact file you'll receive after purchase—no watermarks, no placeholders—just a fully formatted, analysis-ready report crafted for strategic decision-making. It mirrors the final deliverable in layout and content, so what you see is immediately usable for presentations, planning, or client work. Upon purchase you'll get the same editable, print-ready document delivered directly to your inbox—no surprises, no further edits required.
Original: $10.00
-65%$10.00
$3.50Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Visual. Strategic. Downloadable.
Dermapharm’s BCG Matrix preview highlights which brands are gaining market share and which may be cash generators or underperformers amidst shifting OTC and specialty pharma dynamics.
Dive deeper into this company’s BCG Matrix and gain a clear view of where its products stand—Stars, Cash Cows, Dogs, or Question Marks. Purchase the full version for a complete breakdown and strategic insights you can act on.
Buy the full BCG Matrix to receive a detailed Word report + a high-level Excel summary—ready-to-use analysis, quadrant mapping, and tailored recommendations to inform investment and portfolio decisions.
Stars
Arkopharma Natural Health Products
Following full integration by 2025, Arkopharma Natural Health Products is a Star in Dermapharm’s BCG matrix, driving revenue growth—projected to contribute ~28% of group sales (€210m of €750m FY2025e). It holds #1 market share in France and the Iberian Peninsula (combined ~35% market share) and rides a 9–11% CAGR in European plant‑based supplements.
Allergopharma Immunotherapy
Allergopharma Immunotherapy, part of Dermapharm Holding, is a Star in the BCG matrix: it leads European subcutaneous allergy immunotherapy with an estimated 2025 market share around 28% and benefits from a sector CAGR ~7–9% driven by rising environmental sensitivities.
High demand for specialized allergy treatments delivers strong returns—annual revenues near €220m in 2024—but the unit consumes significant cash for R&D, which Dermapharm budgets at ~€25–30m annually to sustain its technological edge.
Specialized Dermatology Portfolio
Dermapharm’s Specialized Dermatology Portfolio is a market leader in Germany, driving ~€420m revenue in 2024 (≈28% of group sales) via high-growth prescription and OTC skin treatments and novel delivery systems like foam and transdermal patches.
The segment covers a large niche therapeutic share—estimated 18% of German topical prescription volume in 2024—but faces intense competition, requiring ongoing promotional spend (≈12% of segment sales) to defend share.
CDMO Biotech Manufacturing
CDMO Biotech Manufacturing is a Stars unit: high growth driven by global demand for complex biologics, with Dermapharm securing major lipid-nanoparticle and vaccine-component contracts totaling ~€420m backlog by end-2025, implying >30% CAGR in CDMO revenue since 2023.
Heavy capex planned: €160m facility upgrades through 2026, EPS dilution risk short-term but pathway to 25–35% group revenue share by 2028 if scale and yields meet targets.
- €420m 2025 CDMO backlog
- 30%+ CDMO revenue CAGR (2023–25)
- €160m capex 2025–26
- Target 25–35% group revenue by 2028
International Expansion Units
Dermapharm’s International Expansion Units, focused on Eastern Europe and select Asian markets, are posting 28–35% CAGR in branded pharma sales since 2021, driven by demand for German-quality products and rapid market-share gains.
These units absorb ~€45–60m annually for manufacturing, registration, and distribution build-out but are projected to reach positive FCF by 2027 as regional margins hit 18–22%.
- 28–35% CAGR since 2021
- €45–60m annual cash burn
- Forecast positive FCF by 2027
- Target regional margins 18–22%
Growth engines: Dermatology, Arkopharma, Allergopharma & CDMO drive FCF by 2027
Stars: Arkopharma, Allergopharma, Specialized Dermatology, CDMO and International units drive growth—2025e sales mix: Arkopharma €210m (28%), Allergopharma €220m, Dermatology €420m, CDMO backlog €420m; capex €160m (2025–26); international burn €45–60m/yr, FCF by 2027.
| Unit | 2025e (€m) | Key metric |
|---|---|---|
| Arkopharma | 210 | 28% group sales |
| Allergopharma | 220 | ~28% EU share |
| Dermatology | 420 | ~28% group sales |
| CDMO | 420 backlog | €160m capex |
What is included in the product
Detailed Word Document
In-depth BCG review of Dermapharm’s portfolio: Stars to invest, Cash Cows to milk, Question Marks to assess, Dogs to divest—with strategic and market context.
Customizable Excel Spreadsheet
One-page overview placing each Dermapharm business unit in a BCG quadrant for quick strategic decisions.
Cash Cows
Dekristol Vitamin D Portfolio
Dekristol is the undisputed market leader in the German Vitamin D segment, holding about 45% value share in 2024 as the market matured with annual growth under 2%.
The brand generates roughly €85–95m EBITDA annually (2024 estimate), providing steady cash flow with minimal marketing or capex needs.
These funds finance Dermapharm’s R&D and rollout of new question marks and bolster star products like X and Y, covering ~20–25% of group R&D spend in 2024.
axicorp Parallel Import Business
As a leading parallel importer in EU pharmaceuticals, axicorp sells high volumes in a mature market with stable demand; FY2024 volumes ~45 million packs, revenue ~€220m, marginal growth ~2% vs 2023.
The firm leverages intra-EU price gaps to deliver cost-effective meds, holding ~12% share in German parallel import segment (2024), keeping gross margins near 18%.
Low capex needs and tight working capital freed ~€40m cash in 2024, funding dividends and reducing net debt by ~€25m.
Keltican and Tromcardin Brands
Keltican and Tromcardin dominate German pharmacy shelves in nerve health and supplements, each holding estimated market shares of ~28% and ~22% respectively in 2024 pharmacy sales (IQVIA data), generating ~€85m combined retail sales annually.
Market volumes are flat since 2021 (CAGR ~0%), so Dermapharm focuses on margin uplift via supply-chain cuts and SKU rationalization, targeting a 150–200 bps gross-margin gain by 2026.
These are cash cows: they fund R&D and M&A while needing only defensive marketing spend (~2–3% of brand sales) to sustain current share.
Dr. Kade Women Health Products
Dr. Kade Women Health Products gives Dermapharm a market-leading position in stable women’s health and proctology segments, capturing an estimated 28% market share in Germany as of 2025 and adding €120m in annual sales in 2024.
High brand loyalty and entrenched physician prescription patterns yield predictable revenues and a gross margin around 62%, making the line a reliable cash generator.
Growth is low (market CAGR ~1% to 2028), so management focuses on margin preservation, cost control, and free cash flow extraction rather than aggressive expansion.
- 2024 sales €120m
- Germany share ~28% (2025)
- Gross margin ~62%
- Market CAGR ~1% to 2028
Core Generic Branded Portfolio
Dermapharm’s core generic branded portfolio, focused on off-patent therapies in Germany, holds ~12–15% share in key categories (source: IQVIA 2025) and generates steady EBITDA margins near 25%, despite low market growth (~1% annually).
These SKUs need minimal R&D and marketing spend, leverage long-term wholesaler and pharmacy contracts, and produced ~€140–160m operating cash flow in 2024, funding new product launches and M&A.
- Stable market share: 12–15% (IQVIA 2025)
- Growth: ~1% p.a.
- EBITDA margin: ~25%
- 2024 operating cash flow: €140–160m
- Low R&D/promotional spend
Dermapharm’s €400–460m cash‑cow portfolio: high margins, low growth funds R&D & payouts
Dekristol, axicorp, Keltican/Tromcardin, Dr. Kade women’s line and core generics are cash cows for Dermapharm, generating predictable free cash flow (~€400–460m combined operating cash flow in 2024) with low growth (0–2% CAGR) and high margins (gross/EBITDA 18–62%), funding R&D, M&A and dividends while needing only defensive spend.
| Brand | 2024 sales/OCF | Share (2024/25) | Growth | Margin |
|---|---|---|---|---|
| Dekristol | €85–95m EBITDA | 45% (2024) | <2% pa | — |
| axicorp | €220m rev / ~€40m cash freed | 12% PI (2024) | ~2% | Gross ~18% |
| Keltican/Tromcardin | ~€85m | 28% /22% (2024) | 0% pa | — |
| Dr. Kade | €120m sales | 28% (2025) | ~1% pa | Gross ~62% |
| Core generics | OCF €140–160m | 12–15% (2025) | ~1% pa | EBITDA ~25% |
Preview = Final Product
Dermapharm Holding BCG Matrix
The BCG Matrix preview shown here is the exact file you'll receive after purchase—no watermarks, no placeholders—just a fully formatted, analysis-ready report crafted for strategic decision-making. It mirrors the final deliverable in layout and content, so what you see is immediately usable for presentations, planning, or client work. Upon purchase you'll get the same editable, print-ready document delivered directly to your inbox—no surprises, no further edits required.
